contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


alligator-bioscience-ab-publ-interim-report-january-march-2019

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Alligator Bioscience is a research-based biotechnology company that uses patented technology to develop biological drug candidates in inflammation and cancer. The company is active in the former part of the drug development chain. Alligator Bioscience has a global technology platform and is active in a rapidly growing segment of the pharmaceutical market - protein drugs. The company was founded in 2001 and is headquartered in Lund, Sweden.

Alligator Bioscience

Significant events January-MarchFirst patient dosed in Phase I clinical study of ATOR-1015.New preclinical data presented demonstrating strong anti-tumor effects for the 4-1BB antibody ATOR-...

<hl2>Significant events January-March</hl2><ul><li>First patient dosed in Phase I clinical study of ATOR-1015.</li><li>New preclinical data presented demonstrating strong anti-tumor effects for the 4-1BB antibody ATOR-1017.</li><li>Alligator Bioscience launched RUBY™, a novel concept in bispecific antibody formats.</li></ul><hl2>Events after the end of the period</hl2><ul><li>Tumor-localizing properties of ATOR-1015 demonstrated by live imaging.</li><li>New preclinical data for ATOR-1144 demonstrates potential for activation of both the innate and the adaptive immune system as well as direct anti-tumor effects.</li></ul>Financial information <hl2>January-March 2019</hl2><ul><li>Net sales, SEK 0.0 million (0.8)</li><li>Total operating costs SEK -46.7 million (-45.0)</li><li>Operating result, SEK -46.2 million (-44.0)</li><li>Earnings per share before and after dilution, SEK -0.62 (-0.59)</li><li>Cash flow for the period, SEK -34.3 million (0.8)</li><li>Cash and cash equivalents, including securities, SEK 402.9 million (436.4)</li></ul>"This is a very exciting year for Alligator. We currently have two projects - ADC-1013 and ATOR-1015 - in clinical development. These projects will soon be joined by ATOR-1017," CEO Per Norlén comments.Read the complete report in the pdf below.The information was submitted for publication at 8:00 a.m. CEST on April 17, 2019.For further information, please contact: Per Norlén, <virtloc>CEO, per.norlen@alligatorbioscience.com, 046-540</virtloc>82 00 Per-Olof Schrewelius, <virtloc>CFO, per-olof.schrewelius@alligatorbioscience.com, 046-540</virtloc>82 03 Cecilia Hofvander, Director IR &amp; <virtloc>Communications, cecilia.hofvander@alligatorbioscience.com, 046-540</virtloc>82 06Alligator Bioscience AB (publ) 556597-8201 Medicon Village, Scheelevägen 2, 223 81 Lund, Sweden Phone +46 46 540 82 00. www.alligatorbioscience.comAbout Alligator Bioscience Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator's growing pipeline includes five lead clinical and preclinical drug candidates: ADC-1013, ATOR-1015, ATOR-1017, ALG.APV-527 and ATOR-1144. Alligator's shares are listed on Nasdaq Stockholm (ATORX). The Company is headquartered in Lund, Sweden, and has approximately 55 employees. For more information, please visit www.alligatorbioscience.com.ADC-1013 (JNJ-7107) is licensed to Janssen Biotech, Inc. for global development and commercialization.